Dr Lipkin is Vice Chair for Research, Weill-Cornell Department of Medicine. He is also a a standing member of the FDA Molecular and Clinical Genetics Panel, which reviews and votes on approval of new genetic tests in the US. He is Director of the Weill Cornell Medical College Genetics Clinic, where he practiced as a Clinical Geneticist and supervise Genetic Counselors in the Departments of Medicine and Genetic Medicine, and Director of the Program in Mendelian Genetics. As a physician-scientist he has published in many well cited journals, including Cell, Cell Stem Cell, Nature Biotechnology, Nature Genetics, Science, Genes and Development, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation, among others. He directs a research laboratory that uses immunology, massively parallel sequencing, computational biology, mouse models, cell culture and genomics to understand the contribution of genetics to, and mechanisms of, hereditary genetic syndromes. Previously he discovered and mechanistically characterized MLH3, a DNA mismatch repair gene colorectal polyposis and cancer predisposition gene, and also identified or co-identified 6 B cell malignancy predisposition genes. One of his current areas of focus is to help drive an international effort to develop and validate a cancer immunoprevention vaccine for Lynch syndrome.
Title of Speech: Immune Surveillance and Cancer Immunoprevention vaccines
Matteo Pellegrini is a biophysicist who has served on the UCLA Life Sciences Division faculty since he joined the Department of Molecular, Cell and Developmental Biology in 2005. Dr. Pellegrini earned his B.A. in Physics at Columbia University and his Ph.D. in Physics at Stanford. He was a postdoctoral fellow at UCLA, where he worked on computational biology. Following his postdoctoral studies, Dr. Pellegrini co-founded a start-up company and later worked for the pharmaceutical company, Merck, before returning to UCLA. His laboratory research centers on the development of novel computational approaches to analyze large-scale genomic data. His present focus is on data produced using the latest generation of high-throughput sequencers. The Pellegrini group is developing suites of tools for the analysis of high-throughput sequencing data such as methC-seq, RNA-seq, and scRNA-seq. These approaches have been used in many settings, including tissue decomposition and biomarker discovery for the study of aging.
Title of Speech: The Effects of Genes, Environment and Physiology on DNA Methylomes
Gary Royle is head of Cancer Engineering at University College London (UCL) and co-chairs UCL’s cross-faculty cancer research network. Having studied mathematics and theoretical physics at Imperial College London he went on to apply that to medicine, with a focus on cancer. Initially developing technologies and methodologies for cancer diagnostics he now leads a large team focusing on cancer therapies for both UCL and UCL Hospital. Research includes radiation oncology, proton therapy, cancer technologies, cancer imaging and computational cancer. The latter includes computational biology, digital pathology and predictive modelling, using a combination of artificial intelligence and analytical methods. He has particular interest in metastatic disease and in understanding and predicting the response of cancers to treatment. He has published >150 papers and leads multi-institutional collaborations and networks in the field of cancer therapeutics. The team also run educational and training programmes for oncology and cancer research in UK and China.
Title of Speech: Predicting Response to Cancer Treatment